Loading...
  • Therapy
  • Although significant advances are occurring in epilepsy research, about 30% of epileptic patients are still inadequately controlled by standard drug therapy. (ovid.com)
  • She is founder and past chair of the BIO Preclinical Safety Expert Group (BioSafe) and was the U.S. BIO Representative to the 2006 ABPI/BIA Early Stage Clinical Trials Taskforce.Dr. Cavagnaro is currently North American Chair of the Drug Information Association-Biotech SIAC and Chair of the Clinical and Regulatory Affairs Committee of the American Society of Gene Therapy. (wiley.com)
  • Evaluation of ovarian follicle development demonstrates that administration of combination therapy using VEGF and FSH-CTP failed to increase follicle vasculature above levels seen with FSH-CTP monotherapy. (biomedsearch.com)
  • Although alternative Bcr-Abl tyrosine kinase inhibitors have been developed to overcome drug resistance, a cocktail therapy of different kinase inhibitors and additional chemotherapeutics may be needed for complete remission of CML in some cases. (nih.gov)
  • metabolism
  • Readers will understand why absorption-distribution-metabolism-excretion-toxicology (ADMET) is key in drug development. (ellibs.com)
  • The mammalian target of rapamycin (mTOR), a serine-threonine protein kinase in the phosphatidylinositol 3-kinase/serine/threonine protein kinase Akt signaling pathway, has an important role in the regulation of protein synthesis, cell proliferation, angiogenesis, and metabolism.Alterations of the mTOR signaling pathway are common in malignancies, including several types of sarcoma.Rapamycin and its analogs (rapalogs) are effective anticancer agents in a broad range of preclinical models. (nih.gov)
  • In this study, 30 FDA-approved anticancer or antiviral drugs were screened for inhibitory effects on Mpn growth and selected analogs were further characterized by inhibition of target enzymes and metabolism of radiolabeled substrates. (nih.gov)
  • efficacy
  • Evaluation of protective efficacy of CC-2 formulation against topical lethal dose of T-2 toxin in mice. (curehunter.com)
  • Despite the urgency to develop and implement novel approaches capable of preventing HIV transmission, this process has been hindered by the lack of adequate small animal models for preclinical efficacy and safety testing. (nih.gov)
  • In conclusion, this thesis has demonstrated that interfering with the metabolic phenotype of cancer can enhance the activity of existing drugs and identified novel analogues of TMZ that circumvent drug resistance mechanisms that hamper the efficacy of TMZ. (brad.ac.uk)
  • Methods
  • Identification of hotspot drug-receptor interactions through in-silico prediction methods (Pharmacophore mapping, virtual screening, 3DQSAR, etc), is considered as a key approach in drug designing and. (bioportfolio.com)
  • anticancer
  • The anticancer drug 6-thioguanine had a MIC (minimum inhibitory concentration required to cause 90% of growth inhibition) value of 0.20 μg ml(-1), whereas trifluorothymidine, gemcitabine and dipyridamole had MIC values of approximately 2 μg ml(-1). (nih.gov)
  • Development
  • 7. Comparison of Preclinical Development Programs for Small Molecules (Drugs/Pharmaceuticals) and Large Molecules (Biologics/Biopharmaceuticals): Studies, Timing, Materials, and Costs ( Christopher Horvath, DVM, MS, DACVP (Archemix Corp.) ). (wiley.com)
  • A Comprehensive Guide to Toxicology in Nonclinical Drug Development, Second Edition , is a valuable reference designed to provide a complete understanding of all aspects of nonclinical toxicology in the development of small molecules and biologics. (elsevier.com)
  • This updated edition has been reorganized and expanded to include important topics such as stem cells in nonclinical toxicology, inhalation and dermal toxicology, pitfalls in drug development, biomarkers in toxicology, and more. (elsevier.com)
  • Discovery
  • This is an enlightening reference for scientists, medicinal chemists, and others working in drug discovery. (ellibs.com)
  • Modified versions of these surrogates should provide agents capable of modifying the activity of these targets and enable one to study their involvement in specific biological processes as a means of target validation for downstream drug discovery. (nih.gov)
  • biological
  • Unlike the case of high-grade gliomas, for which multiple genetic, xenograft, and cell culture models have supported extensive biological and preclinical investigations, low-grade gliomas have been considerably more challenging to model and study. (aacrjournals.org)
  • validation
  • Chemical validation of trypanothione synthetase: a potential drug target for human trypanosomiasis. (curehunter.com)
  • Taken together, these data provide initial chemical validation of TryS as a drug target in T. brucei. (curehunter.com)
  • Proteins
  • A family of immunophilin proteins that bind to the immunosuppressive drugs TACROLIMUS (also known as FK506) and SIROLIMUS. (bioportfolio.com)
  • potential
  • a potential drug target for human trypanosomiasis . (curehunter.com)
  • In the search for new therapeutics for the treatment of human African trypanosomiasis , many potential drug targets in Trypanosoma brucei have been validated by genetic means, but very few have been chemically validated. (curehunter.com)
  • resistance
  • Finally, Temozolomide (TMZ) is an important drug in the treatment of glioblastomas but its activity is reduced by resistance mechanisms including O6 methyl guanine methyltransferase (MGMT) and mismatch repair (MMR). (brad.ac.uk)
  • research
  • Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. (curehunter.com)
  • Realize the full power of the drug-disease research network! (curehunter.com)